After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Meet the Compound: Laquinimod – HD Insights
First patient enrolled in Phase II study evaluating laquinimod
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Teva & Active Biotech Press Release: November 4, 2014
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review | SpringerLink
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
Laquinimod | C19H17ClN2O3 - PubChem
Laquinimod - Wikipedia
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
Letter to investigators involved in the Arpeggio study of Laquinimod …
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
